“4Q17 revenue of $6.93M, up 19.9% y/y, was above both our estimate of $6.62M and consensus of $6.64M. System-wide comp sales grew 26% y/y. GAAP EPS of ($0.02) was slightly narrower than both our estimate and consensus of ($0.03). 2018 guidance issued with revenue bracketing our estimates and above consensus, but adjusted EBITDA below both our estimates and consensus. JYNT plans to open 40-50 franchise clinics, add up to 2 new corporate-owned clinics (greenfields), and purchase up to 3 existing franchises (buybacks).”,” Maxim Group’s analyst wrote.
Several other research analysts have also recently issued reports on JYNT. Zacks Investment Research cut shares of Joint from a buy rating to a hold rating in a report on Wednesday, January 10th. ValuEngine upgraded shares of Joint from a sell rating to a hold rating in a report on Sunday, December 31st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $5.86.
Joint (NASDAQ:JYNT) last issued its earnings results on Thursday, March 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Joint had a negative net margin of 13.01% and a negative return on equity of 66.65%. The firm had revenue of $6.93 million for the quarter, compared to analysts’ expectations of $6.48 million. research analysts forecast that Joint will post 0.08 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. boosted its holdings in Joint by 28.4% in the third quarter. Russell Investments Group Ltd. now owns 112,900 shares of the company’s stock valued at $538,000 after acquiring an additional 25,000 shares in the last quarter. Boston Partners boosted its holdings in Joint by 25.4% in the third quarter. Boston Partners now owns 189,200 shares of the company’s stock valued at $901,000 after acquiring an additional 38,300 shares in the last quarter. Deutsche Bank AG boosted its holdings in Joint by 3,839.1% in the fourth quarter. Deutsche Bank AG now owns 59,087 shares of the company’s stock valued at $293,000 after acquiring an additional 57,587 shares in the last quarter. Skylands Capital LLC boosted its holdings in Joint by 11.0% in the fourth quarter. Skylands Capital LLC now owns 612,529 shares of the company’s stock valued at $3,038,000 after acquiring an additional 60,900 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Joint in the fourth quarter valued at $379,000. Institutional investors and hedge funds own 49.83% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Joint (JYNT) Rating Reiterated by Maxim Group” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/03/13/joint-jynt-rating-reiterated-by-maxim-group.html.
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.